Plaque in Brain

100 million by 2050 - global figure for Alzheimer’s disease patients

Plaque in Brain, Healthy Living Magazine, Anti-aging, Dr Anthony Kleinsmith

Plaque in Brain, Healthy Living Magazine, Anti-aging, Dr Anthony Kleinsmith

A new study demonstrated that neuronal cells pretreated with Proline-rich Polypeptides avoid the accumulation of beta-amyloid, toxic plaque that builds up in brains of Alzheimer’s patients.

You’ve probably never heard of an ultra-tiny amino acid sequence called proline-rich polypeptide. But 39 studies published on PubMed suggest these tiny wunderkinds could provide memory loss protection for an aging population.

Technically speaking, proline-rich polypeptides or PRPs, isolated from first-milking colostrum, are tiny amino acid sequences consisting of 10 chains or fewer, made up of high amounts of proline. Though tiny, they are critical to healthy immune function and activate the thymus gland.

With enhanced immune activity via thymus gland function, the body is able to not only fight off viral and bacterial infections but down regulate inflammation already within the normal range. Now researchers have found these amino acid sequences hold a promising preventive approach for fighting off symptoms of memory loss, including Alzheimer’s.

Alzheimer’s disease is a progressive neurodegenerative and ultimately fatal disease that slowly destroys the brain. Symptoms include progressive impairment of cognitive function including memory loss, inability to think abstractly, loss of language function, attention deficit and associated depression, anxiety and agitation. Eventually Alzheimer’s disease sufferers lose the ability to take care of themselves and must be looked after either by family or in residential care homes and hospitals. Ultimately, sufferers become less resistant to infections and other illnesses, which often become the cause of death.

It is currently estimated that there are already over 10,000,000 Alzheimer’s disease sufferers in the United States, Europe and Japan. Demographic trends predict a dramatic increase in the number of people living to the age of 80 and beyond by the middle of this century. On the basis of current estimates of the incidence of Alzheimer’s disease in the population, the number of sufferers globally could well increase significantly. Taking into account demographic changes in Japan, other Asian countries and the Americas, the global figure for Alzheimer’s disease patients may exceed 100,000,000 by 2050.

Sadly, no new drug has emerged for Alzheimer’s in over a decade, and those that do exist have shown, at best, modest success. That’s why people are desperate to find methods of retarding progression of this condition. First milk has shown encouraging results. Colostrum, also known as first milk, is rich in growth factors, immunoglobulins and other compounds necessary to the proper growth of newborns. All mammals produce colostrum prior to ordinary mother’s milk.

The reason that bovine colostrum, in particular, is desirable is that baby calves are born without almost any innate immunity and also require a high level of growth factors for tissue repair. Thus, bovine colostrum is intended to supplement the newly born baby calf’s immune system until it can become functional, as well as provide growth factors for tissue development. Without colostrum, human babies and certainly calves have higher chances of either becoming sickly or simply die from infections and lack of growth.

As people age, the body’s own production of these immune and growth factors begins to decline dramatically. Colostrum contains more than 90 well-characterized components integral to our health. Its primary components can be divided into immune and growth factors. Colostrum is able to replenish the body’s supplies in a form that is shown to pass through the harsh environment of the digestive tract and into systemic circulation.

Traditional health systems have long recognized that colostrum is a valuable tool for fighting premature aging. Colostrum is prized for its anti-aging and immune boosting qualities throughout Europe and in Indian Ayurveda.

Bio-Medicine reports, “Based on findings of a recent study researchers say that a mixture of peptides derived from colostrum could help slow the progression of Alzheimer’s disease by reducing the build-up of beta amyloid, a toxic protein that accumulates in the brains of Alzheimer’s sufferers.” The report went on, “In a double blind, placebo-controlled trial of 106 people with mild to moderate Alzheimer’s disease published last year it was found that after 15 weeks of taking the product in tablet form, around 40% of the patients were stabilized or had an improved overall response in tests on cognitive function. The greatest effects were seen during the earlier stages of the disease and no serious adverse events were observed during the trial.”

Researchers at the Department of Psychiatry, Wroclaw Medical University, Poland, say that a proline-rich polypeptide complex from colostrum “has shown positive effects in the treatment of Alzheimer’s disease (AD).”

The recently reported study found that Alzheimer’s patients taking tablets of colostrum rich in the complex experienced “statistically significant improvement or stabilization” of their health status. The colostrum-based preparation is a “very promising preparation which can be used to retard the development of AD.”

A study, published July 2009 in the Journal of Nutritional Health and Aging, demonstrated that neuronal cells pretreated with PRPs avoid the accumulation of beta-amyloid, toxic plaque that builds up in brains of Alzheimer’s patients.

In the October 1, 2007 issue of Progress in Neuro- Psychopharmacology & Biological Psychiatry Dr A. Gladkevich of the Department of Psychiatry, University of Groningen, the Netherlands, took note of the growing body of work on PRP and observed, “The development of effective and safe drugs for a growing Alzheimer’s disease population is an increasing need at present. Both experimental and clinical evidence support a beneficial effect of proline-rich polypeptides in a number of neurodegenerative diseases, including Alzheimer’s disease. Experimental data have shown that proline rich polypeptides isolated from bovine neurohypophisis possess neuroprotective and neuromodulatory properties in mice with aluminum neurotoxicosis or neuronal damage caused by venoms and toxins.” Meantime, again it was stated PRPs “have been shown to produce cognitive improvement in an experimental model and in patients with Alzheimer’s disease.”

We also know that PRPs are not specific so that PRP from bovine first-milking colostrum works for all mammals.

Some products available to consumers today are more aptly termed transitional milk products. These contain many fewer of the important anti-aging growth factors and immune-supportive immunoglobulins. Anovite first-milking colostrum, however, is obtained within six hours of the birth of the calf.

Also known as “mother’s milk,” the very highest quality colostrum is limited to the first few hours following the birth of the calf. Because colostrum is highly diluted by milk in the hours following birth, many experts contend that colostrum gathered after more than 10 hours following the birth of the calf should be more aptly termed transitional milk.

Birthing practices differ between New Zealand (where much of the world’s colostrum is produced) and the United States (also a leading producer). Some New Zealand calves are birthed in the pastures, meaning that the colostrum gathered from their mothers is usually harvested later than in America where calving often takes place under supervised and controlled conditions. Some New Zealand colostrum products can be gathered more than 24 hours following the birth and are still called colostrum. Yet, none of these nutritional treasures is available at desirable peak concentrations unless consumers choose true first milking colostrum. Anovite is considered to be a true first-milking colostrum product.

comments powered by Disqus